6598 — Applied BioCode Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual income statement for Applied BioCode, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	105	299	320	390	395
Cost of Revenue
Gross Profit	53	194	189	234	269
Selling / General / Administrative Expenses
Research And Development
Total Operating Expenses	380	433	485	583	582
Operating Profit	-275	-134	-165	-193	-187
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-280	-103	-165	-185	-163
Provision for Income Taxes
Net Income After Taxes	-280	-103	-165	-185	-164
Net Income Before Extraordinary Items
Net Income	-280	-103	-165	-185	-164
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-280	-103	-165	-185	-164
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-4.36	-1.33	-2.02	-2.26	-2
Dividends per Share